Innovations and advancements with prosthetic breast reconstruction
Abstract
Prosthetic breast reconstruction has evolved over the years to provide results that now mimic that of a natural breast. This is due to a variety of innovations and advancements related to mastectomy techniques, acellular dermal matrices, autologous fat grafting, and improved breast implants. The evolution of prosthetic breast reconstruction has gone full‐circle and included prepectoral placement in the 1970s and 80s, partial or total subpectoral placement from 1985 to 2015, and now gradually trending back to prepectoral. There are several techniques and strategies that now allow for patients to achieve results t...
Source: The Breast Journal - March 2, 2018 Category: Cancer & Oncology Authors: Maurice Y. Nahabedian Tags: ORIGINAL ARTICLE Source Type: research
Empyema necessitans mimicking inflammatory breast cancer —An unusual case of breast edema
(Source: The Breast Journal)
Source: The Breast Journal - March 2, 2018 Category: Cancer & Oncology Authors: Suzanne M. Smith Iorfido, Erini Makariou Tags: BREAST IMAGES Source Type: research
Sebaceous carcinoma of the breast: Histological, cytological, and ultrastructural features
(Source: The Breast Journal)
Source: The Breast Journal - March 2, 2018 Category: Cancer & Oncology Authors: Yasuhiro Sakai, Makoto Ohta, Yoshiaki Imamura Tags: BREAST IMAGES Source Type: research
Primary tumor resection in metastatic breast cancer: A propensity ‐matched analysis, 1988‐2011 SEER data base
Abstract
Primary tumor resection (PTR) in metastatic breast cancer is not a standard treatment modality, and its impact on survival is conflicting. The primary objective of this study was to analyze impact of PTR on survival in metastatic patients with breast cancer. A retrospective study of metastatic patients with breast cancer was conducted using the 1988‐2011 Surveillance, Epidemiology, and End Results (SEER) data base. Cox proportional hazards regression models were used to evaluate the relationship between PTR and survival and to adjust for the heterogeneity between the groups, and a propensity score‐matched anal...
Source: The Breast Journal - March 2, 2018 Category: Cancer & Oncology Authors: Nasreen A. Vohra, Jason Brinkley, Swapnil Kachare, Mahvish Muzaffar Tags: ORIGINAL ARTICLE Source Type: research
HER2 equivocal breast cancer that is positive by alternative probe HER2 FISH are classified as HER2 negative by Oncotype DX
Abstract
In breast cancer, human epidermal growth factor receptor 2 (HER2) status is determined by immunohistochemistry (IHC) and/or in situ hybridization. Oncotype DX also reports HER2 status by an rt‐PCR‐based assay. Assay concordance between IHC and fluorescent in situ hybridization (FISH) (including alternative probe HER2 FISH) vs Oncotype DX HER2 rt‐PCR has not been described in the post‐2013 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) HER2 Guideline revision setting. We performed a retrospective review of HER2 equivocal invasive breast carcinoma from 2014 to 2016 with t...
Source: The Breast Journal - March 2, 2018 Category: Cancer & Oncology Authors: Gary H. Tozbikian, Debra L. Zynger Tags: ORIGINAL ARTICLE Source Type: research
Outcomes of outpatient breast cancer surgery at a private breast clinic
Abstract
Advances in surgical and anesthetic techniques have allowed for outpatient treatment of breast cancer. We evaluated the feasibility, safety, efficacy, and surgical outcomes of outpatient surgery in 370 patients with breast cancer who underwent breast‐conserving surgery (BCS)/axillar lymph node (ALN) management. There were no deaths or severe intraoperative complications, but 41 complications were observed and disease recurrence occurred in 18 patients. The cumulative overall survival rate was 95.2%. Outpatient surgery was well tolerated, feasible, and safe in patients receiving BCS/ALN management. (Source: The Breast Journal)
Source: The Breast Journal - March 1, 2018 Category: Cancer & Oncology Authors: Ryungsa Kim, Ami Kawai, Megumi Wakisaka, Yuri Funaoka, Yui Nishida, Naomi Yasuda, Koji Arihiro Tags: SHORT COMMUNICATION Source Type: research
Adjuvant continuous metronomic adriamycin + cyclophosphamide followed by weekly nab ‐paclitaxel for high‐risk early‐stage breast cancer
Abstract
Many studies have sought to optimize the dosing schedule of adjuvant chemotherapy in early‐stage breast cancer. Here, we assessed the use of continuous metronomic weekly doxorubicin plus daily oral cyclophosphamide (AC) with continuous G‐CSF growth factor support for 12 weeks followed by weekly nab‐paclitaxel (nP) for 12 weeks. A nonrandomized phase II clinical trial was designed to assess (1) DFS at 2 years, (2) dose delivered, (3) use of nP in the adjuvant setting, and (4) toxicities. The dosing of A was 24 mg/m2 IV weekly and C was 60 mg/m2 oral daily (with scheduled filgrastim 5mcg/kg 6 days/week); nP, 1...
Source: The Breast Journal - March 1, 2018 Category: Cancer & Oncology Authors: Eunpi Cho, Qian Wu, Lena Rubinstein, Hannah Linden, Julie Gralow, Jennifer Specht, Vijayakrishna Gadi, Georgiana Ellis Tags: SHORT COMMUNICATION Source Type: research
Evaluating the risk of underlying malignancy in patients with pathologic nipple discharge
Abstract
Most pathologic nipple discharge (PND) is benign, but duct excision has been advised to exclude malignancy. To identify factors associated with malignancy, we reviewed 280 patients with PND at our institution from 2004 to 2014. In 49 cases, malignancy was found. These patients more often had palpable masses (39% vs 11%, P < .001) and abnormal imaging (94% vs 75%, P = .004). On multivariable analysis, age, palpable mass, and abnormal imaging were independently associated with malignancy. Among 48 patients with PND but no other clinical/imaging abnormalities, only 1 malignancy, a small ductal carcinoma in si...
Source: The Breast Journal - March 1, 2018 Category: Cancer & Oncology Authors: George Z. Li, Stephanie M. Wong, Susan Lester, Faina Nakhlis Tags: SHORT COMMUNICATION Source Type: research
Indications for biopsy of imaging ‐detected intramammary and axillary lymph nodes in the absence of concurrent breast cancer
Abstract
To evaluate the prevalence of malignancy in imaging‐detected abnormal lymph nodes (LNs) in women without concurrent cancer and to identify imaging features predictive of malignancy in this population. This is an IRB‐approved study with waived informed consent. We retrospectively reviewed medical records of all image‐guided LN FNAs and CNBs performed at our institution from 1/1/08 through 12/31/10. LNs sampled in patients without concurrent breast cancer comprised our study group (SG; n = 77), and with concurrent breast cancer our reference group (RG; n = 124). Blinded to cytology/histology, imaging featu...
Source: The Breast Journal - March 1, 2018 Category: Cancer & Oncology Authors: Vandana Dialani, Christine Westra, Shambhavi Venkataraman, Valerie Fein ‐Zachary, Alexander Brook, Tejas Mehta Tags: ORIGINAL ARTICLE Source Type: research
Clinicopathologic analysis of a large series of microinvasive breast cancers
The Breast Journal, EarlyView. (Source: The Breast Journal)
Source: The Breast Journal - February 24, 2018 Category: Cancer & Oncology Source Type: research
Distinguishing papillary endothelial hyperplasia and angiosarcoma on core needle biopsy of the breast: The importance of clinical and radiologic correlation
The Breast Journal, EarlyView. (Source: The Breast Journal)
Source: The Breast Journal - February 24, 2018 Category: Cancer & Oncology Source Type: research
The case for the omission of axillary staging in invasive breast carcinoma that exhibits a predominant tubular growth pattern on preoperative biopsy
The Breast Journal, EarlyView. (Source: The Breast Journal)
Source: The Breast Journal - February 24, 2018 Category: Cancer & Oncology Source Type: research
Does the presence of sentinel lymph node macrometastases in breast cancer patients require axillary lymph node dissection? —Single‐center analysis
The Breast Journal, EarlyView. (Source: The Breast Journal)
Source: The Breast Journal - February 24, 2018 Category: Cancer & Oncology Source Type: research
---
The Breast Journal, Ahead of Print. (Source: The Breast Journal)
Source: The Breast Journal - February 24, 2018 Category: Cancer & Oncology Source Type: research
